Key Highlights
•
Plasma p-tau181 levels are significantly elevated in patients with ALS and ALS-FTD compared to healthy controls, and increase over one year while a standard biomarker (NfL) remains stable. This suggests p-tau181 reflects a different, peripheral disease process in ALS, offering a new and complementary biomarker that is mechanistically distinct from NfL.
Source →
•
A study integrating polygenic and transcriptional risk scores from blood samples found that individuals with high scores for both had a 2.5-fold to 3.4-fold higher risk of Alzheimer’s disease. This combined approach improved early detection accuracy across diverse populations, providing a less invasive and more accessible alternative to traditional biomarkers.
Source →
Stay curious. Stay informed —
Science Briefing
